Impact-TD

Impact-TD, Tardive Dyskinesia

Objective

Impact-TD 

Teva Pharmaceuticals is running a Phase 4 clinical trial to evaluate how effective the medication Austedo is in treating Tardive Dyskinesia (TD). Participants must be 18 years of age or older, have a diagnosis of TD or possible TD.

Status: Active, not Recruiting

Clinical Trial Categories

  • Tardive Dyskinesia (TD)
How to Participate

For more information please email

khamoudeh@newbridgehealth.org

Contact me

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.